References
ATS/ERS Statement (2003) American thoracic society/European respiratory society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 168:818–900
Bach G, Zeigler M, Zlotogora J (2007) Prevention of lysosomal storage disorders in Israel. Mol Genet Metab 90:353–357
Baruch S, Pollitz K, Gruber J (2008) GINA Q and a transcript. Genet Public Policy Cent 3(2008):1–9
Beaudet A (1990) Invited editorial: carrier screening for cystic fibrosis. Am J Hum Genet 47:603–605
Bell C, Dinwiddie D, Miller N, Hateley S, Ganusova E, Mudge J et al (2011) Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med 3:65ra4
Borry P, Hennemen L, Lakeman P, Kate L, Cornel M, Howard H (2011) Preconception genetic carrier testing and the commercial offer directly-to-consumers. Hum Reprod 26(5):972–977. doi:10.1093/humrep/der042
Caskey CT, Kaback MM, Beaudet AL (1990) The American society of human genetics statement on cystic fibrosis screening. Am J Hum Genet 46:393
Castellani C, Macek M, Cassiman J, Duff A, Massie J, Kate L, Barton D, Cutting G, Dallapiccola B et al (2010) Benchmarks for cystic fibrosis carrier screening: a European consensus document. J Cyst Fibros 9:165–178
Committee Opinion 469 (2010) Carrier screening for fragile X syndrome. Obstet Gynecol 116(4):1008–1010
Committee Opinion 432 (2009) Spinal muscular atrophy. Obstet Gynecol 113(5):1194–1196
Committee Opinion 442 (2009) Preconception and prenatal carrier screening for genetic diseases in individuals of eastern European Jewish descent. Obstet Gynecol 14(4):950–953
Committee Opinion 486 (2011) Update on carrier screening for cystic fibrosis. Obstet Gynecol 117(4):1028–1031
Darcy D, Tian L, Taylor J, Schrijver I (2011) Cystic fibrosis carrier screening in obstetric clinical practice: knowledge, practices, and barriers, a decade after publication of screening guidelines. GenetTest Mol Biomarkers 15(7–8):517–523
de Serres FJ, Blanco I, Fernandez-Bustillo E (2010) Ethnic differences in alpha-1 antitrypsin deficiency in the United States of America. Ther Adv Respir Dis 4:63–70
Dondorp W, de Wert G (2013) The “thousand-dollar genome”: an ethical exploration. Eur J Hum Genet 21:S6–S26
ESHG (2010) Statement of the ESHG on direct-to-consumer genetic testing for health-related purposes. Eur J Hum Genet 18:1271–1273
Evans P (2011) Looking ahead, looking behind. Genet Med 13(3):177–178. doi:10.1097/GIM.0b013e318210b0a7
Grody W, Cutting G, Klinger K, Richards C, Watson M, Desnick R (2001) Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med 3(2):149–154
Grody W, Thompson B, Gregg A, Bean L, Monaghan K, Schneider A, Lebo R (2013) ACMG position statement on prenatal/preconception expanded carrier screening. Genet Med 15:482–483
Henneman L, Bramsen I, Van Der Ploeg HM, Ten Kate LP (2002) Preconception cystic fibrosis carrier couple screening: impact, understanding and satisfaction. Genet Test 6:195–202
Jahnke CM, Stark E, Terry SF, Bonhomme N (2012) Is this a genesis in prenatal testing: genomic knowledge, risk or benefit? Genet Test Mol Biomarkers 16(12):1347–1348
Karem B, Rommens J, Buchanan J, Markiewicz D, Cox T, Chakravarti A (1989) Identification of the cystic fibrosis gene: genetic analysis. Science 245(4922):1073–1080
Lazarin GA, Haque IS, Nazareth S, Lori K, Patterson AS, Jacobson JL et al (2012) An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23,452 individuals. Genet Med 15(3):178–186. doi:10.1038/gim.2012.114
Levenson D. (2010). New test could make carrier screening more accessible. The AJMG SEQUENCE, vii-viii
Lewis C, Skirton H, Jones R (2012) Reproductive empowerment: the main motivator and outcome of carrier testing. J Heal Psychol 17:567–578
McGee D, Schwarz L, McClure R, Peterka L, Rouhani F, Brantly M, Strange C (2010) Is PiSS alpha-1 antitrypsin deficiency associated with disease? Pulm Med. doi:10.1155/2010/570679
Prior T (2008) Carrier screening for spinal muscular atrophy. Genet Med 10(11):840–842
Rosner G, Rosner S, Orr-Urtreger A (2009) Genetic testing in Israel: an overview. Annu Rev Genom Human Genet 10:175–192
Srinivasan B, Evans EA, Flannick J, Patterson AS, Chang CC, Pham T et al (2010) A universal carrier test for the long tail of Mendelian disease. Reprod BioMed Online 21:537–551
Stoller, Aboussouan (2012) A review of α1-antitrypsin deficiency. Concise clinical review. Am J Repiratory Crit Care Med 185(3):246–259. doi:10.1164/rccm.201108-1428CI
Sveger T (1976) Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 294:1316–1321
Sveger T, Thelin T (2000) A future for neonatal α1-antitrypsin screening? Acta Paediatr 89:628–631
Tatsugawa ZH, Fox MA, Fang CY, Novak JM, Cantor RM, Bass HN et al (1994) Education and testing strategy for large-scale cystic fibrosis carrier screening. J Genet Couns 3:279–289
Teckman JH (2007) α1-Antitrypsin deficiency in childhood. Sem Liver Dis 27(3):274–281. doi:10.1055/s-2007-985072
Van El C, Cornel M, on behalf of ESHG PPPC (2011) Genetic testing and common disorders in a public health framework. Eur J Hum Genet 19:S1–S5
Van El C, Cornel M, Borry P, Hastings R, Fellmann F, Hodgson S, Howard H et al (2013) Whole-genome sequencing in health care. Eur J Hum Genet 21:580–584
Compliance with ethics guidelines
All research done in the development of this article complied with the current laws of the USA.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wienke, S., Brown, K., Farmer, M. et al. Expanded carrier screening panels—does bigger mean better?. J Community Genet 5, 191–198 (2014). https://doi.org/10.1007/s12687-013-0169-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12687-013-0169-6